Development and Evaluation of a ChlorHexidine Gluconate bAthing pRotocol for Healthcare Settings in Low- and Middle-income Countries

Last updated: June 30, 2025
Sponsor: University of Pennsylvania
Overall Status: Terminated

Phase

N/A

Condition

Bacterial Infections

Treatment

Chlorhexidine Gluconate (CHG)

Clinical Study ID

NCT06590675
855362
  • Ages 1-6
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The overall goal of the ChlorHexidine gluconate (CHG) bAthing pRotocol for healthcare settings in low- and Middle-income countries (CHARM) study is to explore the safety, efficacy and feasibility of utilizing a locally prepared CHG solution and bathing protocol among hospitalized neonates to reduce bacterial colonization and healthcare-associated infection (HAI) burden in hospitalized patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Neonates 1-6 days old admitted to the neo-natal unit expected to stay at least 7days

Exclusion

Exclusion Criteria:

  • Patients with a current weight of <1kg

  • Patients with a current corrected gestational age of <28 weeks (by Ballard score, orby dates if Ballard is not done)

  • Patients with a current diagnosis of hypothermia

  • Patients with a current diagnosis of skin rash or skin injury

Study Design

Total Participants: 19
Treatment Group(s): 1
Primary Treatment: Chlorhexidine Gluconate (CHG)
Phase:
Study Start date:
February 19, 2025
Estimated Completion Date:
March 19, 2025

Study Description

Neonatal sepsis is the third most common cause of neonatal deaths and multidrug-resistant Gram-negative bacteria are now the leading cause of sepsis among hospitalized neonates in south Asia and sub-Saharan Africa, including Botswana. Multidrug-Resistant Organism (MDRO) colonization is thought to precede infection, meaning that pathogens usually are transferred to the skin or intestinal mucosa where they live prior to translocating to the bloodstream or other sterile body compartments, triggering an inflammatory response recognized as clinical sepsis. Colonization is established through direct or indirect contact between a patient and a reservoir that harbors the pathogen.

Multidisciplinary infection prevention and control (IPC) practices can reduce the risk of neonatal MDRO colonization, but once colonized, newborns run the risk of acquiring a serious infection with a difficult-to-treat organism. The use of ancillary IPC measures, including chlorhexidine gluconate (CHG) bathing, has been studied as a de-colonization measure among hospitalized patients. CHG bathing is widely used in Intensive Care Units (ICUs) across high-income countries to reduce bacterial colonization with pathogens, and is being used more frequently in Neonatal Units (NNUs) in low and middle-income countries (LMICs) as a sepsis prevention measure.

The investigators of the CHARM study have developed a protocol to accomplish the following goals:

  1. develop a low-cost, standardized protocol for CHG bathing in the ICU and NNU

  2. assess safety of local CHG preparation among hospitalized neonates

  3. determine the efficacy of CHG bathing using the developed protocol to reduce bacterial colonization and healthcare-associated infection (HAI) burden in hospitalized patients

  4. to assess the feasibility and acceptability of CHG bathing among staff and caregivers

The investigators will utilize a mixed methods study involving both a prospective interventional cohort study following approximately 240 neonates, and qualitative interviews of 10 caregivers and 20 healthcare workers in the NNU and ICU.

Connect with a study center

  • Princess Marina Hospital

    Gaborone,
    Botswana

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.